ST. LOUIS, Aug. 20, 2025 /PRNewswire/ — Centene Corporation (NYSE: CNC) (Centene) announced today that it received notice of an unsolicited “mini-tender” offer from TRC Capital Investment Corporation (TRC) dated August 5th, 2025. Centene is in no way affiliated with TRC. TRC has offered to purchase up to 4 million shares of Centene’s common stock at… Continue reading CENTENE CORPORATION RECOMMENDS STOCKHOLDERS REJECT “MINI-TENDER” OFFER FROM TRC CAPITAL INVESTMENT CORPORATION
Author: PR Newswire Online News
KASOWITZ LLP: ENVESTNET, INC. WAS FOUND TO HAVE ACTIVELY PARTICIPATED IN SPOLIATION AND NOW FACES A DELAWARE JURY TRIAL ON FINANCIALAPPS’ $100 MILLION TRADE SECRET MISAPPROPRIATION CLAIM
NEW YORK, Aug. 20, 2025 /PRNewswire/ — Six years into a $100 million lawsuit brought by Kasowitz LLP on behalf of fintech pioneer FinancialApps, LLC against defendants Envestnet, Inc. and Yodlee, Inc. for trade secret misappropriation, tortious interference, and unfair competition, a Special Master appointed by the Delaware District Court has recommended formal sanctions against both Envestnet (recently acquired… Continue reading KASOWITZ LLP: ENVESTNET, INC. WAS FOUND TO HAVE ACTIVELY PARTICIPATED IN SPOLIATION AND NOW FACES A DELAWARE JURY TRIAL ON FINANCIALAPPS’ $100 MILLION TRADE SECRET MISAPPROPRIATION CLAIM
Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight
The demand for minimal residual disease testing is increasing mainly due to the higher prevalence of solid tumors and blood cancers like leukemia, multiple myeloma, and lymphoma. Continuous advances in molecular diagnostics have greatly improved MRD detection accuracy, and active product development and launches by leading companies are further boosting the market’s momentum. LAS VEGAS,… Continue reading Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight
CTO Realty Growth, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the CTO Class Action
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired CTO Realty Growth, Inc. (NYSE: CTO) securities between February 18, 2021 and June 24, 2025. CTO is a publicly traded real estate investment trust (“REIT“) that owns and operates a… Continue reading CTO Realty Growth, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the CTO Class Action
Biohaven Ltd. Stockholders are Urged to Seek Representation to Lead the BHVN Class Action: Contact Robbins LLP for More Information
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025. Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology. The… Continue reading Biohaven Ltd. Stockholders are Urged to Seek Representation to Lead the BHVN Class Action: Contact Robbins LLP for More Information
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases.… Continue reading ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.
NVO STOCK: Robbins LLP Reminds NVO Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Novo Nordisk A/S
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025. Novo Nordisk is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical… Continue reading NVO STOCK: Robbins LLP Reminds NVO Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Novo Nordisk A/S
LINE STOCK: Robbins LLP Reminds LINE Stockholders of the Opportunity to Lead to the Class Action Lawsuit Against Lineage, Inc.
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with the Company’s 2024 initial public offering (“IPO”). Lineage is a Maryland REIT focused on temperature-controlled cold-manage… Continue reading LINE STOCK: Robbins LLP Reminds LINE Stockholders of the Opportunity to Lead to the Class Action Lawsuit Against Lineage, Inc.
HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma, representing a potential expansion into solid tumors. Quisinostat (Viriom) is in Phase II for uveal melanoma, and Entinostat, partnered between EOC Pharma and Syndax, is being explored in Hodgkin… Continue reading HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight
Lockheed Martin Corporation Stock News: LMT Investors with Large Losses Should Contact Robbins LLP for Information About Leading the LMT Class Action Lawsuit
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025. Lockheed Martin is an aerospace defense company. For more information, submit a form, email attorney Aaron Dumas,… Continue reading Lockheed Martin Corporation Stock News: LMT Investors with Large Losses Should Contact Robbins LLP for Information About Leading the LMT Class Action Lawsuit